Guardant Health, Inc. GH

Company Overview

Guardant Health, Inc. is a precision oncology company that develops and commercializes blood-based and tissue-based molecular diagnostic tests, commonly referred to as liquid biopsies. The company operates within the biotechnology and clinical diagnostics industries, with a primary focus on oncology. Its technologies are designed to detect genomic alterations in cancer, enabling treatment selection, therapy monitoring, and disease recurrence detection using minimally invasive methods.

The company’s core revenue is generated from clinical diagnostic testing and biopharmaceutical services, primarily through its proprietary liquid biopsy platforms. Guardant Health serves oncologists, hospitals, biopharmaceutical companies, and research institutions, with a strategic emphasis on advanced cancer diagnostics and early cancer detection. Founded in 2012, the company has evolved from a single-product diagnostics firm into a multi-platform oncology diagnostics provider, achieving multiple regulatory approvals and expanding into population-scale cancer screening research.